Lucence is a genomic medicine company that invents blood-based tests for cancer screening and treatment selection.
Lucence's mission is to achieve early cancer detection, better treatment and less suffering through deep genome intelligence.
Lucence was founded as a spun out of Singapore’s Agency for Science, Technology and Research (A*STAR) in 2016 by Min-Han Tan. The company is headquartered in Singapore and Palo Alto, California. Lucence also has offices in Hong Kong and China.
Lucence pioneers ultrasensitive liquid biopsy tests and state-of-the-art data analytics for early cancer detection and treatment selection.
Lucence developed its flagship next-generation sequencing test, LiquidHALLMARK®, the first and only clinical sequencing blood test that detects both cancer-related gene mutations and cancer-causing viruses within a single assay.
Lucence's LiquidHALLMARK® detects clinically relevant mutations across 14 cancer types, including lung, breast, colorectal, pancreatic, nasopharyngeal and liver cancers. The test has been used by oncologists in cancer diagnosis, monitoring and treatment selection for over 1,000 patients in Asia to date.
The LiquidHALLMARK® test is based on Lucence’s core molecular watermarking technology, AmpliMARK™, for improved accuracy and depth in sequencing results. In 2019, Lucence’s Singapore central laboratory became the first laboratory in Southeast Asia to be CLIA-certified and CAP-accredited in order to bring LiquidHALLMARK® to physicians and patients in the United States.
Lucence is backed by IHH Healthcare, Temasek Holdings subsidiary Heliconia Capital, SGInnovate and others. The company raised $20M in Series A round on Nov 20, 2019. This brings Lucence's total funding to $29.2M to date.